US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Simplify High Yield ETF

22.05

-0.0048-0.02%

Volume:13.57K

Turnover:299.37K

Market Cap:483.34M

PE:- -

High:22.08

Open:22.08

Low:22.04

Close:22.05

52wk High:24.89

52wk Low:21.77

Shares:21.93M

Float Shares:21.93M

Volume Ratio:0.66

T/O Rate:0.06%

Dividend:1.70

Dividend Rate:7.71%

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Celldex Expands Into Asthma: Early CDX-622 Trial Signals New Growth Angle for CLDX

Arvinas Presents Preclinical Data Supporting Mechanistic Synergies and Enhanced Antitumor Activity with the Combination of ARV-393 and Glofitamab at the 2025 American Society of Hematology Annual Meeting and Exposition

Press Release: BBOT Reports Third Quarter 2025 Financial Results and Update on Corporate Progress

Celldex Announces Initial Positive Results from Phase 1 Trial of CDX-622 Demonstrating Favorable Safety and PK Profile and Sustained Mast Cell Inhibition

Preclinical Data Presented at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics Support Potential of BBO-10203, a First-in-Class RAS:PI3Kα Breaker That Inhibits KRAS-Mutant Tumor Growth without Inducing Hyperglycemia

Want To Ride The Private Credit Boom? Simplify's New ETF Is Built For It

Benzinga_recent_news

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/CDX/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"CDX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CDX\",,,,,undefined,":{"symbol":"CDX","market":"US","secType":"STK","nameCN":"Simplify High Yield ETF","latestPrice":22.0452,"timestamp":1770822366103,"preClose":22.05,"halted":0,"volume":13572,"delay":0,"changeRate":-0.000217687074829908,"floatShares":21925001,"shares":21925001,"eps":0,"marketStatus":"Trading","change":-0.0048,"latestTime":"02-11 10:07:57 EST","open":22.08,"high":22.08,"low":22.035,"amount":299367.280836,"amplitude":0.002041,"askPrice":22.06,"askSize":200,"bidPrice":21.98,"bidSize":500,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1770843600000},"marketStatusCode":2,"adr":0,"exchange":"ARCA","adjPreClose":22.05,"sharesOutstanding":21925001,"nav":22.06,"aum":483557967.81,"dividendRate":0.077078,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":22.05,"preClose":22.05,"latestTime":"16:10 EST","volume":12,"amount":264.6,"timestamp":1770757805125,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.656251},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CDX\",,,,,undefined,":{"symbol":"CDX","floatShares":21925001,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.656251,"shares":21925001,"dividePrice":1.6992,"high":22.08,"amplitude":0.002041,"preClose":22.05,"low":22.035,"week52Low":21.77,"pbRate":"--","week52High":24.89,"institutionHeld":0,"latestPrice":22.0452,"committee":0.428571,"eps":0,"divideRate":0.077078,"volume":13572,"delay":0,"ttmEps":0,"open":22.08,"prevYearClose":22.27,"prevWeekClose":21.94,"prevMonthClose":22.135,"prevQuarterClose":22.27,"fiveDayClose":21.95,"twentyDayClose":22.2975,"sixtyDayClose":22.665},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/CDX\",params:#limit:5,,,undefined,":[{"date":"2026-01-27","symbol":"CDX","amount":0.15,"announcedDate":"2026-01-26","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-01-27","defaultRemindTime":1769524200000,"name":"Simplify High Yield ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-01-30","payableDate":"2026-01-27","currency":"USD","dateTimestamp":1769490000000,"payDate":"2026-01-30"},{"date":"2025-11-21","symbol":"CDX","amount":0.15,"announcedDate":"2025-11-20","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-11-21","defaultRemindTime":1763735400000,"name":"Simplify High Yield ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-11-28","payableDate":"2025-11-21","currency":"USD","dateTimestamp":1763701200000,"payDate":"2025-11-28"},{"date":"2025-10-28","symbol":"CDX","amount":0.15,"announcedDate":"2025-10-27","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-10-28","defaultRemindTime":1761658200000,"name":"Simplify High Yield ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-10-31","payableDate":"2025-10-28","currency":"USD","dateTimestamp":1761624000000,"payDate":"2025-10-31"},{"date":"2025-09-25","symbol":"CDX","amount":0.15,"announcedDate":"2025-09-24","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-09-25","defaultRemindTime":1758807000000,"name":"Simplify High Yield ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-09-30","payableDate":"2025-09-25","currency":"USD","dateTimestamp":1758772800000,"payDate":"2025-09-30"},{"date":"2025-08-26","symbol":"CDX","amount":0.15,"announcedDate":"2025-08-25","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-08-26","defaultRemindTime":1756215000000,"name":"SIMPLIFY HIGH YIELD PLUS CREDIT HEDGE ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-08-29","payableDate":"2025-08-26","currency":"USD","dateTimestamp":1756180800000,"payDate":"2025-08-29"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"CDX\",market:\"US\",,,undefined,":[{"executeDate":"2022-03-28","recordDate":"2022-03-29","paymentDate":"2022-03-31","value":0.0631,"currency":"USD"},{"executeDate":"2022-04-26","recordDate":"2022-04-27","paymentDate":"2022-04-29","value":0.08882,"currency":"USD"},{"executeDate":"2022-05-25","recordDate":"2022-05-26","paymentDate":"2022-05-31","value":0.10303,"currency":"USD"},{"executeDate":"2022-06-27","recordDate":"2022-06-28","paymentDate":"2022-06-30","value":0.09614,"currency":"USD"},{"executeDate":"2022-07-26","recordDate":"2022-07-27","paymentDate":"2022-07-29","value":0.06047,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"CDX\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"CDX\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2605887481","title":"Celldex Expands Into Asthma: Early CDX-622 Trial Signals New Growth Angle for CLDX","url":"https://stock-news.laohu8.com/highlight/detail?id=2605887481","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605887481?lang=en_us&edition=fundamental","pubTime":"2026-01-22 00:37","pubTimestamp":1769013451,"startTime":"0","endTime":"0","summary":"Celldex Therapeutics ($CLDX) announced an update on their ongoing clinical study. Study Overview: Celldex Therapeutics is launching a Phase 1 study...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/celldex-expands-into-asthma-early-cdx-622-trial-signals-new-growth-angle-for-cldx?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/celldex-expands-into-asthma-early-cdx-622-trial-signals-new-growth-angle-for-cldx?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CDX","BK4139","CLDX"],"gpt_icon":0},{"id":"2589825171","title":"Arvinas Presents Preclinical Data Supporting Mechanistic Synergies and Enhanced Antitumor Activity with the Combination of ARV-393 and Glofitamab at the 2025 American Society of Hematology Annual Meeting and Exposition","url":"https://stock-news.laohu8.com/highlight/detail?id=2589825171","media":"GlobeNewswire","labels":["productRelease","conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589825171?lang=en_us&edition=fundamental","pubTime":"2025-12-06 21:05","pubTimestamp":1765026300,"startTime":"0","endTime":"0","summary":"– Data support initiation of a combination cohort in the ongoing Phase 1 clinical trial to evaluate ARV-393 plus glofitamab as a chemotherapy-free combination approach in diffuse large B-cell lymphoma","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/06/3201049/0/en/Arvinas-Presents-Preclinical-Data-Supporting-Mechanistic-Synergies-and-Enhanced-Antitumor-Activity-with-the-Combination-of-ARV-393-and-Glofitamab-at-the-2025-American-Society-of-He.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TGI","BK4107","BK4117","BK4187","IE00B19Z4B17.USD","CDX","IE00B66KJ199.SGD","AFG","IE00B7SZL793.SGD","IE0031619046.USD"],"gpt_icon":0},{"id":"2583886845","title":"Press Release: BBOT Reports Third Quarter 2025 Financial Results and Update on Corporate Progress","url":"https://stock-news.laohu8.com/highlight/detail?id=2583886845","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583886845?lang=en_us&edition=fundamental","pubTime":"2025-11-13 05:05","pubTimestamp":1762981500,"startTime":"0","endTime":"0","summary":"-- BBOT debuted as a publicly traded company focused on optimized target. coverage for patients with tumors driven by RAS and PI3K<ALPHA> and a. synergistic portfolio that is designed to enable targeted KRAS. -- Advanced three ongoing Phase 1 clinical trials, with clinical data. -- Cash runway expected to fund BBOT operations into 2028. -- Appointed industry veteran Uneek Mehra as Chief Financial Officer. \"The third quarter marked an exciting period for BBOT as we made our debut on Nasdaq and welcomed industry veteran Uneek Mehra as our Chief Financial Officer,\" said Eli Wallace, PhD, Chief Executive Officer of BBOT. \"We continue to advance a robust pipeline of next-generation KRAS and PI3K<ALPHA> inhibitors designed to target the RAS pathway, which is one of the most commonly dysregulated in oncology. With three internally discovered clinical assets progressing toward key data readouts in 2026 and a strong financial position expected to fund operations into 2028, we are well positione","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NQmain","PRGS","CDX","BBOT","BK4097","BK4139","LU2065732104.USD"],"gpt_icon":0},{"id":"2579172541","title":"Celldex Announces Initial Positive Results from Phase 1 Trial of CDX-622 Demonstrating Favorable Safety and PK Profile and Sustained Mast Cell Inhibition","url":"https://stock-news.laohu8.com/highlight/detail?id=2579172541","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579172541?lang=en_us&edition=fundamental","pubTime":"2025-10-31 04:01","pubTimestamp":1761854460,"startTime":"0","endTime":"0","summary":"--Data from Phase 1 Study in healthy volunteers presented at CIA Biennial Symposium-- HAMPTON, N.J., Oct.  30, 2025  (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced todaypositive data from the ong","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/10/30/3177884/24180/en/Celldex-Announces-Initial-Positive-Results-from-Phase-1-Trial-of-CDX-622-Demonstrating-Favorable-Safety-and-PK-Profile-and-Sustained-Mast-Cell-Inhibition.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PK","CDX"],"gpt_icon":0},{"id":"2578509376","title":"Preclinical Data Presented at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics Support Potential of BBO-10203, a First-in-Class RAS:PI3Kα Breaker That Inhibits KRAS-Mutant Tumor Growth without Inducing Hyperglycemia","url":"https://stock-news.laohu8.com/highlight/detail?id=2578509376","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578509376?lang=en_us&edition=fundamental","pubTime":"2025-10-26 00:30","pubTimestamp":1761409800,"startTime":"0","endTime":"0","summary":"Data demonstrate BBO-10203 blocks RAS-mediated activation of PI3Kα and strongly inhibits pAKT signaling in tumor cells without affecting glucose metabolismRobust monotherapy activity, as well as combi","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/10/25/3174172/0/en/Preclinical-Data-Presented-at-the-2025-AACR-NCI-EORTC-International-Conference-on-Molecular-Targets-and-Cancer-Therapeutics-Support-Potential-of-BBO-10203-a-First-in-Class-RAS-PI3K.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GEM","LENZ","LU0264606111.USD","BK4007","BK1550","BK1184","LU0572939691.SGD","PDX","01336","LU0572940350.SGD","BK4539","BK4202","NCI","BK4139","CDX","BK1584"],"gpt_icon":0},{"id":"2570045105","title":"Want To Ride The Private Credit Boom? Simplify's New ETF Is Built For It","url":"https://stock-news.laohu8.com/highlight/detail?id=2570045105","media":"Benzinga_recent_news","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2570045105?lang=en_us&edition=fundamental","pubTime":"2025-09-26 02:54","pubTimestamp":1758826440,"startTime":"0","endTime":"0","summary":"Simplify Asset Management launched the Simplify VettaFi Private Credit Strategy ETF (NYSE: PCR), tapping into one of the most talked-about themes in 2025: private credit.","market":"us","thumbnail":"https://cdn.benzinga.com/files/images/story/2025/09/25/ETFs.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2025/09/25/ETFs.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/etfs/new-etfs/25/09/47875681/want-to-ride-the-private-credit-boom-simplifys-new-etf-is-built-for-it","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/etfs/new-etfs/25/09/47875681/want-to-ride-the-private-credit-boom-simplifys-new-etf-is-built-for-it","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["BK4550","FDN","BK4588","CDX","BK4585"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":6,"code":"91000000","status":"200"}]}}